EyePoint receives third positive DSMC recommendation for Phase 3 wet AMD DURAVYU trials

EyePoint, Inc.

DSMC recommends LUGANO and LUCIA continue without modification; all active treatment-arm patients have received second DURAVYU dose.
Over 35% of patients have received third planned dose at Week 56; safety profile consistent with >190 patients across prior trials.
Topline data from LUGANO expected mid-2026; LUCIA readout to follow shortly after.
Trials enroll over 900 patients; primary endpoint is non-inferiority in mean BCVA change at weeks 52 and 56.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.